Discovery of MK-1832, a Kv1.5 inhibitor with improved selectivity and pharmacokinetics.

Abstract Selective inhibition of Kv1.5, which underlies the ultra-rapid delayed rectifier current, I Kur , has been pursued as a treatment for atrial fibrillation. Here we describe the discovery of MK-1832, a Kv1.5 inhibitor with improved selectivity versus the off-target current I Ks , whose inhibition has been associated with ventricular proarrhythmia. MK-1832 exhibits improved selectivity for I Kur over I Ks (>3000-fold versus 70-fold for MK-0448), consistent with an observed larger window between atrial and ventricular effects in vivo (>1800-fold versus 210-fold for MK-0448). MK-1832 also exhibits an improved preclinical pharmacokinetic profile consistent with projected once daily dosing in humans.